- Open Access
Effect of one comprehensive education course to lower anxiety and depression among Chinese breast cancer patients during the postoperative radiotherapy period - one randomized clinical trial
Radiation Oncologyvolume 13, Article number: 111 (2018)
We investigated the effectiveness of one education course to lower the severity of anxiety and depression symptoms among breast cancer (BC) patients during radiotherapy (RT).
All 290 one-sided BC patients were evenly randomized into intervention or control arm. “Intervention” patient was additionally provided with one three-hour course on psychological stresses and management skills. Changes of anxiety and depression score and their 3-level severity category (‘normal’, ‘borderline’ and ‘abnormal’ scored 0–7, 8–10 and 11–21, respectively) from HADS questionnaire over RT were evaluated by multivariable linear and ordinal logistic regressions.
Response rates were 94 and 100% by “intervention” and “control” arm, respectively. Means of score changes by “intervention” and “control” (n = 145) were + 0.59 (SD = 2.47) and + 0.11 (SD = 2.55) for anxiety and + 0.81 (SD = 2.81) and + 0.45 (SD = 2.77) for depression scores, respectively. ‘Abnormal’ anxiety and depression patients were 4.1 and 6.9% at baseline and 4.8 and 6.9% at end of RT at ‘control’ arm; those rates were 6.6 and 7.4%, and 8.8 and 10.3% at ‘intervention’ arm, respectively. Both changes on anxiety and depression measurements between two arms were all insignificant (p > 0.20).
One education course did not reduce the score and severity of anxiety and depression symptoms over RT period.
Chinese Clinical Trial Registry #: ChiCTR-IIR-16008818 at www.chictr.org.cn.
Anxiety and depression are commonly observed among breast cancer (BC) patients over any period of cancer screening, breast lump imaging, cancer diagnosis, treatments, and tumor recurrence, and surveillance follow-up [1,2,3,4,5,6,7]. Especially for BC patients who are experiencing the intensive treatments, anxiety and depression contribute various signs and symptoms which often indicate or heighten the pain expectancy, sleep disturbances, gastrointestinal symptoms, poor compliance with medications, and thus further complicate BC management . As frequently observed, many studies have demonstrated that anxiety and depression at any level could substantially interfere with the quality of life (QoL) of patient and possibly his/her survival if not evaluated and treated timely [2, 9, 10].
The exact etiological mechanism of BC associated anxiety and depression is still unclear. However, many studies have found that both medical and non-medical factors are deeply involved in the emergence of anxiety and depression [1, 11]. Young age, female, black and Asia races, limited cancer knowledge, active treatments, and the life-changing complications as results of therapies have been identified as the contributing factors [4, 7, 12, 13]. More specifically, BC surgery (either lumpectomy or mastectomy) and other treatments including chemotherapy (CTx), radiotherapy (RT), and endocrine therapy (ET), are found to be the most significant elements in exacerbating these psychological symptoms [14,15,16,17]. There are many other factors also involved such as marital status (either single or divorced), low social status (like education and income), lack of insurance, and unemployment [18, 19]. Although there are reportedly as high as 40–80% prevalent rates of anxiety and depression symptoms, only 3–5% of BC patients have experienced psychosocial distress serious enough to meet the disorder diagnosis under the fourth revised edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) at any time point forward after BC diagnosis [20, 21]. Nonetheless, given the high prevalence of anxiety and depression, BC patients especially those who undergo the series of therapy modalities, are strongly recommended by guidelines to undergo regular, psychosocial assessments with professionals like psychiatrist, psychologist, or pastoral counselors especially over the subsequent CTx and RT episodes after the surgery [22, 23]. Therefore, how to minimize the impact of anxiety and depression symptoms on QoL of BC patients systemically has become one challenging but essential part of BC integrated medical care [24,25,26]. The timely prevention and intervention are clinically required.
Similar to the management on chronic diseases like diabetes mellitus and hypertension, education regarding BC as a form of non-pharmacologic interventions has been found to be associated with higher patient compliance of ET, regular exercise, and healthy and well-balanced diets [27, 28]. Some clinical studies have also shown that the early educational or psychological interventions could lower the incidence and severity of anxiety and depression symptoms and improve their survival [29,30,31,32]. Similarly to other countries, the necessary postoperative RT and ET in China are administered after the surgery and 6–8 cycles of CTx. With fear to RT and side effects of CTx and ET, many BC patients at this stage have experienced the anxiety and depression symptoms of poor appetite, nervousness, panic, sadness, tiredness, apathy, sleeping disorder, feelings of worthlessness and helplessness, and even suicidal tendency [17, 33,34,35]. At this stage, the adequate education on RT knowledge including high energy x ray from accelerator, new technique of using three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) with good control of dosage on normal organ at risk was found by some studies to be able to reduce some fears and anxious feelings [36,37,38]. Therefore, one overdue comprehensive education course on BC and its managements before RT could be theoretically effective. Given these findings, we designed one randomized clinical trial (RCT) to test whether educational intervention prior to RT can impact the anxiety and depression symptoms presented among RT eligible BC patients.
The objective of this trial was to determine if a comprehensive education course on BC disease knowledge and its management can significantly reduce the incidence and/or severity of anxiety and depression symptoms measured through The Hospital Anxiety and Depression Scale (HADS) during the RT period among Chinese BC patients.
Study design and participants
This study was a two-arm, one centre, randomized, phase 3 trial comparing the effectiveness of one education course versus none impacting the anxiety and depressoin symptom severities among BC patients during RT. All BC patients admitted for postoperative RT at the Fourth Hospital of Hebei Medical University from Nov. 2013 to Feb. 2015 were screened for this trial enrollment by two study coordinators with handouts. The inclusion criteria included female, age ≥ 18 years old, one-sided BC diagnosis, the modified radical mastectomy (MRM) or breast conserving surgery (BCS) performed within 6 months, ECOG performance score 0 or 1, and signed Informed Consent Form (ICF). The exclusion criteria included recurrence, pregnant women, dementia, the history of alcohol or narcotics abuse, current or past diagnosis or treatment of psychological or psychiatric disorders, current use of any Chinese herbs, and inability to understand the HADS questionnaires even with oral help from family members. The study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University. Under the trial proposal, two hundred and ninety BC patients were enrolled into this study.
Randomization and intervention
Each enrolled patient was randomly allocated (in a 1:1 ratio) into either “intervention” (I) or “control” (C) arms immediately after the ICF signature was obtained and by using a randomization schedule. The schedule was generated from using SAS procedure Proc PLAN with block size 4. Masking was not used in this trial. The patient, study coordinator, researcher and others were aware of the assigned procedures. Under the standard medical care guideline of the hospital, all patients were offered a15-minute educational course on basic knowledge of BC and RT on the admission day. For “I” patient only, one comprehensive education course designed for this trial was scheduled at one meeting room. The content of the three-hour course was formulated by the study team in advance and was delivered in slides and question/answer format twice weekly by two well-trained physician researchers prior to the patient’s first RT session. Only one course was allowed for each patient to attend during the entire study period. In brief, the entire course covered the BC basics (breast anatomy, cancer development, diagnosis, staging, treatment, and survivorship) in plain language with emphasis on BC-related psychiatry and psychology management. It also provided many didactic presentations such as psychosocial and nutrition intervention skills. In short, the interventional tools included the timely consultation with the primary care physician, group-talking techniques and healthy lifestyle maintenance (healthy diet, sufficient sleep, and regular exercise) in order to reduce BC-related stress symptoms. Because of individual reasons, a few “I” arm patients did not attend the course after one attempt of reminders and one course rescheduling failed.
Trial size calculation
The HADS has been widely used to measure distress in BC patients [39,40,41]. Its Chinese version has also been validated and used among Chinese BC patients in several studies with good reliability estimates of Cronbach’s α over 0.80 for anxiety and depression subscale [42,43,44]. The hypothesis of this trial was that one education course would reduce the mean of anxiety or depression score measured by HADS to be less than 0.5 (defined as the minimal detectable and clinical meaningful difference). Under a randomized two-arm parallel trial design, a total 242 patients would be required to detect a intervention difference at a two-side α = 0.01 significant level with β = 90% probability power.
Demographic and clinical data at baseline
All demographic and key clinical data were collected through the pre-defined case report form at baseline which was defined as the signed date of ICF. Data included age, height, weight, marital status, highest level of education, self-reported income level, menopause status, BC side, TNM stage, and surgery type (MRM vs. BCS). Body mass index (BMI) was calculated from weight (kg) divided by squared height in meters.
The hospital anxiety and depression scale measure and delivery
All patients were asked to fill in the HAD questionnaire within ±1 day of the first and last RT date. The first measurement was mandatory and reported as the baseline score. In literature, both English and Chinese versions of the HAD questionnaire have been validated in many studies for cancer patients [41, 44]. In brief, it consists of 14 items and contributes to two subscales of anxiety (HADS-A) and depression (HADS-D) domains. Both HADS-A and HADS-D scores are calculated from the sum of 7 different item scores in a four-point Likert scale 0 to 3. A high score of HADS-A or HADS-D indicates high levels of anxiety and depression severity, respectively. To categorize the measures, three levels of ‘normal’, ‘borderline’ and ‘abnormal’ are classified by the score range of 0–7, 8–10 and 11–21 for each subscale . In this study, both continuous and categorical HADS-A and HADS-D measured changes were analyzed. Both HADS-A and HADS-D items presented high internal consistency with the calculated Cronbach’s α coefficient range 0.80–0.85. In addition, the binary ‘abnormal’ status change of patient at each subscale was analyzed as well. Please note that the score changes of the HADS-A and HADS-D subscales were defined as the score at the end of RT minus the baseline one.
Per the protocol, all patients filled the HADS questionnaire on site herself with one written instruction available while one research staff and one immediate family member (optional) could be there for assistance if needed . All “I” arm patients attended the education course in 0–5 days after the HADS questionnaire was filled. The patient was not allowed to access the baseline records of HADS at the second time of filling.
Radiotherapy and hormonal treatment
For each patient, RT was delivered through 3DCRT or IMRT with 6-MV protons of accelerator at the discretion of individual treating physicians. All patients completed the planned RT therapy in doses of 50Gy/25 fractions/5–6 weeks for the chest and supraclavicular lymph node regions for MRM patients, and 50Gy/25 fractions/5–6 weeks for the whole breast plus the tumor bed with β rays boost 10 Gy/5 fractions/1 week for BCS patients. Under the study protocol, less than 5 consecutive day of RT interruption was allowed in case of treating radiation dermatitis, lymphatic edema, and bone marrow suppression. For all patients with positive ER or PR (defined as > 2% cells), the hormonal treatments of taking mainly Tamoxifen or Letrozol were provided since the admission. No chemotherapy was used during the RT sessions.
Descriptive statistics were used to characterize the patient demographic and clinical data collected at baseline. To compare means or percents between two groups, student’s t-test and Chi-square test (the exact test if applicable) were used, respectively. Simple ANOVA was applied for mean comparisons among more than two groups. To account for the confounding effects of covariates on means or multinomial level percents, the multivariable linear regression (MLR) and multinomial ordered logistic regression (MOLR) models were used for referential analyses. Age, surgery type (MRM vs. BCS), TNM stage, education level, and self-rated income group were considered stratifying factors or covariates in these analyses. HT treatment status was finally excluded from the covariate list given its consistent insignificant effects found in all statistical models. For presentation, the estimated coefficient and their associated p value were cited from the univariate linear regression and MLR models. From the MOLR models, the Odd Ratio (OR) and its 95% confidence interval (CI) were presented. All statistical analyses were conducted using SAS v9.2 (SAS Institute, Cary, NC). The significance level was two-sided p ≤ 0.05.
Participants and analysis population
Overall, 290 patients who met the study inclusion and exclusion criteria and signed the ICF were randomized into the study. Each arm enrolled 145 patients. However, nine (6.2%) of 145 “I” patients were excluded from the analysis because they did not attend the education course at all. Per the protocol, the analysis population was defined as the randomized patients who actually attended the education course, and filled at least one item of the HADS at baseline. No score imputations for the missing HADS items were conducted given that only two (< 1%) patients in the analysis population did not respond 1–2 items either at baseline or after RT due to the apparent negligence. Given the nature of this study, the intention-to-treatment (ITT) population was not chosen for analysis.
Table 1 shows the balanced demographic and clinical characteristics of the analysis population overall and by study arm. Among the total 281 patients in the analyzed population, the means were 46.2 years old for age and 26.8 kg/m^2 for BMI. The majority (97.5%) had MRM and 51.6% were diagnosed with left-sided BC. In terms of pathological TNM stage, 19 (6.8%) patients were ‘undetermined’ because their primary tumor size exact records could not be found from charts, and 51.6% (145/281) were classified as stage II, and 29.9% (84/281) as stage III. By self-reported income level, 25.6% patients claimed themselves to be ‘poor’ and no one reported having ‘high’ income. No statistical differences between the two arms on demographic and clinical data were found (Table 1). Because only one patient reported as ‘single’, the marriage status (data not shown) was not analyzed.
Anxiety and depression score and severity
At baseline and completion of RT (i.e. after RT), both anxiety and depression scores did not show significant differences between the two arms (Table 2). However, the anxiety score was significantly increased from its baseline mean 5.15 to 5.49 after RT (p = 0.02, t-test) but with the same median 5.0 (p > 0.05, median test). The depression score also increased significantly from its baseline mean (median) 4.79 (4.0) to 5.40 (5.0) after RT (both t and median test p values = 0.00). Among the score-based severity levels, the ‘abnormal’ anxiety percent increased from baseline 5.3% (15/279) to the RT end 6.8% (19/279). And the ‘abnormal’ depression percent also increased from baseline 7.1% (20/218) at baseline to the RT end 8.5% (24/201). However, the simple independent proportion comparison tests did not show any difference of the ‘abnormal’ rates of both anxiety and depression between baseline and ‘after RT’. To accurately appreciate the differences of their changes between the two study arms, both linear and ordered logistic regression model analyses were applied.
Changes of anxiety and depression score over RT
Table 3 presents the comparisons of the anxiety and depression score changes between two study arms and by other demographic and disease character groups at baseline. Overall, the anxiety and depression score changes were significantly positive with overall means of + 0.34 and + 0.62 respectively (both paired t-test p < 0.05, comparing with zero). Their 95%CIs of the mean differences of anxiety and depression were estimated to be 0.05–0.64 and 0.29–0.95, respectively. However, the insignificant median test on the anxiety (p = 0.14, test if the population median values equal 0) did not support its score increase. The median test supported the significant depression score increase over RT.
Through simple ANOVA analyses, Table 3 indicated that there were no significant differences of anxiety or depression score changes over RT between or among the two arms, age group, TNM stage, tumor side and surgery type with all p > 0.10. However, low education and poor income levels were found to associate with high increase of anxiety score at significant (p = 0.01) and marginally significant levels (p = 0.06), respectively. Regression analyses were subsequently conducted to compare the score change of anxiety and depression between the two arms. Table 4 presented the results of univariate and MLR analyses which showed there were no significant differences of both changes between the “I” and “C” arms (all p values > 0.10). While the education level was found to be negatively and significantly associated with high anxiety increase at univariate and MLR models (both p = 0.01, data not shown), none of the other covariates contributed significantly to either anxiety or depression score changes (data not presented in Table 4). Surprisingly, the BCS patients tended to have marginally statistical larger increase scores of anxiety and depression changes (both p = 0.06) at MLR models only (data not showed in Table 4 either).
Changes of anxiety and depression level over RT
To understand how anxiety and depression severity levels changed differently between ‘I’ and ‘C’ arms, both basic and multivariable MOLR models were conducted. Please note that these analyses should be considered to be supplemental to the score change analyses above and would be more meaningful in clinical aspects (Table 5). That is to say, the three levels of anxiety and depression scores - ‘normal’, ‘borderline’ and ‘abnormal’ - were collectively analyzed in order to reduce the possible significant impact of individual score assessment sensitivity variations on analysis result. Table 2 (low part) showed that the percents of ‘normal’, ‘borderline’ and ‘abnormal’ anxiety scores at baseline were 79.0%, 15.0 and 5.3%, respectively. At the end of RT, these percents were 75.4, 17.1 and 6.8%, respectively. In consideration of depression severity level, these percents were 77.6, 15.3 and 7.1% at baseline, and 71.5, 18.9 and 8.5% at end of RT. The same covariates at MLR models were utilized at MOLR analyses. The basic MOLR model had the independent variables of the trial arm and levels of score-based anxiety or depression severity only. Table 5 demonstrated that the baseline anxiety and depression severity level significantly contributed to their corresponding levels at end of RT (all p values < 0.001) in all models. With regard to anxiety or depression levels, ‘I’ patients had no statistical differences of their changes over RT, compared to the ‘C’ patients. However, the adjusted OR (95%CI, p value) from multivariable MOLR models for anxiety was calculated as 1.244 (0.688–2.316, 0.492) for anxiety and 1.415 (0.743–2.696, 0.291) for depression levels. The results of both ORs being no statistically different than 1.000 suggested that ‘Intervention’ had no significant impact in moving up or down the levels of anxiety or depression over the RT period.
Through extensive analyses, this trial found that both anxiety and depression scores measured in HADS increased over RT course, however, their 3-level category (normal, borderline, abnormal) percents had not significant change. Also, this trial concluded that one comprehensive educational course on BC knowledge with emphasis on teaching stress management skills did not lead to significant changes in either score or category changes of anxiety and depression over the 5–6 weeks of postoperative RT. While its long-term effect still awaits the follow-up data, several aspects are worthy of discussion.
First, this trial studied BC patients admitted for postoperative RT and its conclusion should be interpreted and applied in this setting. Compared to BC patients who do not need postoperative RT, they usually have larger tumors and more metastatic regional lymph nodes in China where the prevalence of patient with early stage BC is still relatively low . Indeed, the ‘abnormal’ rates of having anxiety and depression before RT in this study were as high as 5.3 and 7.1%, respectively. Some prospective studies reported that 3–5% patients at any time point after BC diagnosis met the diagnostic criteria of anxiety and depression under the DSM-IV-TR [20, 21]. In this regard, it is reasonable to believe that BC patients with incoming RT would require more educational courses including RT or longer time for full recovery of distress than other BC populations. In fact, one RCT of 126 BC patients admitted for RT has confirmed the effectiveness of the enhanced knowledge of RT and disease on improving the anxiety and QoL over time from first RT to 3 months after . Therefore, the repetitive and comprhensive courses of BC and its treatments may be more valuable.
Second, the secondary finding of education rather than income level being negatively associated with high anxiety increase needs a careful review. Liteature review seems not to be consistently supportive for this point. Schwarz et al. followed 367 women with breast (n = 174) or gynecological (n = 193) cancer over 12 months after initial treatments and found the low educational level are at high risk of maintaining high anxiety and depression scores (HADS) over time . However, de Moor studied 487 women with newly diagnosed BC ductal carcinoma in situ (DCIS) and found that instead of education, the financial status was inversely associated with changes in anxiety and depression over 9 months after diagnosis . Chen et al. analyzed 1400 Chinese women with stage 0-IV BC and found that the low income and unmarried marital status were two independent predictors for depression at 18 months post-diagnosis . Given the interacted complex of education, employment, income and marriage, we tended to collectively believe that it would be the socioeconomic status (SES) negatively influence the anxiety and depression symptoms. The low SES often make the adaption process of psycholgical disorders to be longer and harder.
Third, whether and how the Chinese race and culture influenced the trial results is unknown. Lam et al. compared 348 Chinese and 292 German women with breast cancer and found that German reported more anxiety and depression (both p < 0.001) and prioritized physical and psychological support . However, You et al. reported that Chinese BC patients (n = 97) had higher levels of state anxiety and stronger association of anxiety with QoL than US patients (n = 62) after controlling for demographic and medical characteristics . Many researchers often used the social and cultural differences to explain for the racial disparities in depression and anxiety. Lu et al. reported that following the Confucian values, Chinese BC patients often choose to suppress internal emotion, motivation and avoid social cognition and communication of her illness . Also, Chinese cancer patients usually have low health literacy, financial difficulty, advanced stage of disease at initial presentation, and low quality of cancer care compared with US and Europe patients [54, 55]. The authors believe that all of the above could signficantly contribute to development of higher prevalence and severity anxiety and depression in Chinese BC patients.
Like others, this trial has several limitations. Although the Chinese version of HADS has been validated and used in many studies, a few studies still questioned its diagnostic role to assess anxiety and depression . Therefore, the conclusion of statistically insignificant effect of one education course intervention from this study should be treated cautiously. In addtion, this study did not collect the physical activity, exercise and diet data. Recent studies found that their enhancements have positive effects on fatigue and favorable improvement on anxiety and depression over RT period [57, 58]. If the strong BC disease knowledge and management skills can effectively translate into healthy diet, good sleep and regular exercise could not be verified in this study. One study found that the objective measured moderate-to-vigorous physical activity positively associated with health-related QoL indicators including fatigue, depression, and anxiety . One trial of 6-month exercise and hypocaloric healthy eating intervention among 85 BC patients showed a reduction in depressive symptoms .
Other limitations of this study included there were no objective measurement data on BC knowledge and skill, the official income, and insurance type being collected. Although both multivariable linear and ordinal logistic regressions were conducted and had reached the same conclusion, the assumed balance between the two randomly-assigned arms could not be confirmed. However, there was no reason to believe that they could reverse the conclusion either. Furthermore, the extended ITT analysis (i.e. included nine “I” arm patients who were excluded from the analyses) did not change the conclusion either. Last, the follow-up measures scheduled at 3 and 5 years in this trial may have new findings.
Finally, it is worthy to note that this study found that these BC patients increased their anxiety and depression scores during the RT period. The RT related complications of poor appetite, gastrointestinal symptoms, slow swelling and pain of breast and arm, and dermatitis could be the causative elements. Further studies of evaluating and managing these causes during RT are warranted.
The clinical implications of this study should exceed the negative finding itself. The moderate high prevalence of anxiety and depression symptoms exists among RT eligible Chinese BC patients and over RT period. A wide range of interrelated risk factors from both disease and non-disease aspects contribute to this dynamic complex overtime. The effective educational and psychological interventions are much needed and tailored to this particular population.
Compared to the usual care at admission, one additional comprehensive and intensive education course of BC disease and stress management skills did not reduce the anxiety and depression score and severity over the RT period among Chinese patients. Its long-term effect awaits the follow-up data.
Three-dimensional conformal radiotherapy
Breast conserving surgery
Body mass index
The Diagnostic and Statistical Manual of Mental Disorders
The Hospital Anxiety and Depression Scale
Informed Consent Form
Multivariable linear regression
Multinomial ordered logistic regression
Modified radical mastectomy
Quality of life
Randomized clinical trial
Christensen S, Zachariae R, Jensen AB, et al. Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat. 2009;113(2):339–55.
Hegel MT, Moore CP, Collins ED, Kearing S, et al. Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer. Cancer. 2006;107(12):2924–31.
Clough-Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with change in emotional well-being. J Clin Oncol. 2007;25(11):1334–40.
Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirezet A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005;330:702.
Keyzer-Dekker CM, van Esch L, de Vries J, et al. An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease. Breast Cancer Res Treat. 2012;134(1):253–8.
Yang HC, Thornton LM, Shapiro CL, Andersen BL. Surviving recurrence: psychological and quality-of-life recovery. Cancer. 2008;112(5):1178–87.
Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(11 Suppl):2565–76.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.
Northouse LL, Mood D, Kershaw T, et al. Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol. 2002;20(19):4050–64.
Watson M, St James-Roberts I, Ashley S, et al. Factors associated with emotional and behavioural problems among school age children of breast cancer patients. Br J Cancer. 2006;94(1):43–50.
Jim HS, Andrykowski MA, Munster PN, Jacobsen PB. Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med. 2007;34(2):200–8.
Vin-Raviv N, Hillyer GC, Hershman DL, et al. Racial disparities in posttraumatic stress after diagnosis of localized breast cancer: the BQUAL study. J Natl Cancer Inst. 2013;105(8):563–72.
Champion VL, Wagner LI, Monahan PO, et al. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer. 2014;120(15):2237–46.
Frick E, Tyroller M, Panzer M. Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: a cross-sectional study in a community hospital outpatient Centre. Eur J Cancer Care (Engl). 2007;16(2):130–6.
Karasawa K, Horikawa N, Kawase E, et al. Assessment of psychological responses in patients about to receive radiotherapy. Radiat Med. 2005;23(7):478–84.
Takahashi T, Hondo M, Nishimura K, et al. Evaluation of quality of life and psychological response in cancer patients treated with radiotherapy. Radiat Med. 2008;26:396–401.
Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. Symptoms and symptom attribution among women on endocrine therapy for breast Cancer. Oncologist. 2015;20(6):598–604.
Bidstrup PE, Christensen J, Mertz BG, Rottmann N, Dalton SO, Johansen C. Trajectories of distress, anxiety, and depression among women with breast cancer: looking beyond the mean. Acta Oncol. 2015;54(5):789–96.
Stanton AL, Wiley JF, Krull JL, et al. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. Breast Cancer Res Treat. 2015;154(1):105–15.
Mehnert A, Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology. 2007;16(3):181–8.
Voigt V, Neufeld F, Kaste J, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;26(1):74–80.
Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast Cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–35.
Maunsell E, Brisson J, Deschênes L, Frasure-Smith N. Randomized trial of a psychologic distress screening program after breast cancer: effects on quality of life. J Clin Oncol. 1996;14(10):2747–55.
Carlson LE, Groff SL, Maciejewski O, Bultz BD. Screening for distress in lung and breast cancer outpatients: a randomized controlled trial. J Clin Oncol. 2010;28(33):4884–91.
Golden-Kreutz DM, Thornton LM, Wells-Di Gregorio S, et al. Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients. Health Psychol. 2005;24(3):288–96.
Costanzo ES, Lutgendorf SK, Mattes ML, et al. Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer. 2007;97(12):1625–31.
Heisig SR, Shedden-Mora MC, von Blanckenburg P, et al. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology. 2015;24(2):130–7.
Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology. 2009;18(12):1261–72.
Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer. 2008;113(12):3450–8.
Antoni MH, Lehman JM, Kilbourn KM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol. 2001;20(1):20–32.
Antoni MH, Wimberly SR, Lechner SC, et al. Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry. 2006;163(10):1791–7.
Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345(24):1719–26.
Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.
Dunn LB, Aouizerat BE, Cooper BA, et al. Trajectories of anxiety in oncology patients and family caregivers during and after radiation therapy. Eur J Oncol Nurs. 2012;16(1):1–9.
Aboalela N, Lyon D, Elswick RK Jr, et al. Perceived stress levels, chemotherapy, radiation treatment and tumor characteristics are associated with a persistent increased frequency of somatic chromosomal instability in women diagnosed with breast Cancer: a one year longitudinal study. PLoS One. 2015;10(7):e0133380.
Gillan C, Abrams D, Harnett N, Wiljer D, Catton P. Fears and misperceptions of radiation therapy: sources and impact on decision-making and anxiety. J Cancer Educ. 2014;29(2):289–95.
Nathoo D. Video material as an effective educational tool to address informational and educational needs of cancer patients undergoing radiation therapy. J Cancer Educ. 2017;32(2):219–27.
Halkett GK, Schofield P, O'Connor M, et al. Development and pilot testing of a radiation therapist-led educational intervention for breast cancer patients prior to commencing radiotherapy. Asia Pac J Clin Oncol. 2012;8(3):e1–8.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.
Love AW, Kissane DW, Bloch S, Clarke D. Diagnostic efficiency of the hospital anxiety and depression scale in women with early stage breast cancer. Aust N Z J Psychiatry. 2002;36(2):246–50.
Osborne RH, Elsworth GR, Sprangers MA, Oort FJ, Hopper JL. The value of the hospital anxiety and depression scale (HADS) for comparing women with early onset breast cancer with population-based reference women. Qual Life Res. 2004;13(1):191–206.
Ho SS, So WK, Leung DY, Lai ET, Chan CW. Anxiety, depression and quality of life in Chinese women with breast cancer during and after treatment: a comparative evaluation. Eur J Oncol Nurs. 2013;17(6):877–82.
Hong JS, Tian J. Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. Support Care Cancer. 2014;22(2):453–9.
So WK, Marsh G, Ling WM, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. Eur J Oncol Nurs. 2010;14(1):17–22.
Hinz A, Krauss O, Hauss JP, et al. Anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care (Engl). 2010;19(4):522–9.
Zhang BL, Sivasubramaniam PG, Zhang Q, et al. Trends in radical surgical treatment methods for breast malignancies in China: a multicenter 10-year retrospective study. Oncologist. 2015;20(9):1036–43.
Siekkinen M, Pyrhönen S, Ryhänen A, Vahlberg T, Leino-Kilpi H. Psychosocial outcomes of e-feedback of radiotherapy for breast cancer patients: a randomized controlled trial. Psychooncology. 2015;24(5):515–22.
Schwarz R, Krauss O, Höckel M, Meyer A, Zenger M, Hinz A. The course of anxiety and depression in patients with breast cancer and gynaecological cancer. Breast Care (Basel). 2008;3(6):417–22.
de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer. 2010;116(5):1218–25.
Chen X, Zheng Y, Zheng W, Gu K, Chen Z, Lu W, Shu XO. Prevalence of depression and its related factors among Chinese women with breast cancer. Acta Oncol. 2009;48(8):1128–36.
Lam WW, Au AH, Wong JH, Lehmann C, Koch U, Fielding R, Mehnert A. Unmet supportive care needs: a cross-cultural comparison between Hong Kong Chinese and German Caucasian women with breast cancer. Breast Cancer Res Treat. 2011;130(2):531–41.
You J, Lu Q, Zvolensky MJ, Meng Z, Garcia K, Cohen L. Anxiety- and health-related quality of life among patients with breast cancer: a cross-cultural comparison of China and the United States. J Global Oncol. 2018;4:1–9.
Lu Q, Yeung NC, You J, Dai J. Using expressive writing to explore thoughts and beliefs about cancer and treatment among Chinese American immigrant breast cancer survivors. Psychooncology. 2016;25(11):1371–4.
Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014 Jun;15(7):e279–89.
Wang JW, Shen Q, Ding N, Zhang TR, Yang ZQ, Liu C, Chen SJ, Berry HL, Yuan ZP, Yu JM. A qualitative exploration of the unmet psychosocial rehabilitation needs of cancer survivors in China. Psychooncology. 2016;25(8):905–12.
Whelan-Goodinson R, Ponsford J, Schönberger M. Validity of the hospital anxiety and depression scale to assess depression and anxiety following traumatic brain injury as compared with the structured clinical interview for DSM-IV. J Affect Disord. 2009;114(1–3):94–102.
Travier N, Velthuis MJ, Steins Bisschop CN, et al. Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial. BMC Med. 2015;13:121.
Steindorf K, Schmidt ME, Klassen O, et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol. 2014;25(11):2237–43.
Phillips SM, Awick EA, Conroy DE, Pellegrini CA, Mailey EL, McAuley E. Objectively measured physical activity and sedentary behavior and quality of life indicators in survivors of breast cancer. Cancer. 2015;121(22):4044–52.
Saxton JM, Scott EJ, Daley AJ, et al. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Res. 2014;16(2):R39.
Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to their contents of identifiers of individual patients. However, the de-identified datasets will be available from the corresponding author once the manuscript has been accepted for publication.
Ethics approval and consent to participate
The study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University in China on September 30, 2013. The approval letter # was documented as the file named as “C-20130930” in Chinese.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.